SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amid a Q3 delivery and earnings beat forecast, with the community discussing potential for the stock to reach all-time highs. Some traders point to technical breakouts and hedge fund activity as potential catalysts, while others cite Elon Musk's recent activity and political commentary as concerning. Discussions also include the potential impact of rate cuts and the company's advancements in AI and robotics.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities (ASST) is trending due to its reverse merger with Strive Enterprises, a move anticipated to trigger a short squeeze and a strategic pivot towards Bitcoin asset management. The community is focused on the high short interest, potential forced buy-ins, and the possibility of news regarding Bitcoin purchases. Discussions also involve the technical aspects of trading platforms updating post-merger and the implications of a new CUSIP number.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending due to its recent listing on major exchanges like Binance and Coinbase, sparking significant price movement and high trading volume. The community is buzzing with excitement, discussing potential price targets and anticipating further gains. Many are drawing comparisons to other successful tokens and highlighting the project's strong backing and potential for growth in the decentralized finance (DeFi) space.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending as community members discuss its correlation with Ethereum's price movement and potential rate cuts. Investors are also reacting to news, including commentary from Jim Cramer and insights from Tom Lee. Bullish sentiment seems to be building around BMNR's potential as a crypto treasury and its strategic positioning in the Ethereum ecosystem.

Memecoin on Injective taken over by the community.

Nonja

$NONJA.X is trending due to growing excitement around its potential as the top meme coin on the Injective blockchain ($INJ.X), particularly with the anticipated benefits from Injective's growing ecosystem and upcoming ETFs; community members are highlighting its strong fundamentals, burned liquidity, unique NFT collection and engaged community, with many anticipating significant gains as Injective gains wider recognition.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community discusses a potential short squeeze fueled by strong Q3 delivery numbers and future growth expectations. Investors are optimistic due to William Li's Q4 delivery guidance and the recurring revenue potential from Battery-as-a-Service. Discussion also centers on NIO's battery swap stations and their potential role in China's energy grid.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending as traders discuss its potential in the energy storage sector, particularly for data centers, and its possible role in the renewable energy transition. The company's financial health and potential for a short squeeze are also being debated by investors, along with the significance of its new software suite, DawnOS.

Towns

TOWNS.X is trending amid community excitement and volatility, with some users suggesting it's primed for a run while others caution about potential dumps. The conversation includes references to other cryptocurrencies like AVNT.X and PUMP.X, with some users moving between them in pursuit of profits.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement and anticipation surrounding an upcoming investor summit. The community is speculating on potential news from the conference and the possibility of a short squeeze, given the stock's low float. Some traders are wary, citing past reverse splits and potential dilution.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto "crow with knife" ($CAW.X) is gaining attention, with community members actively chanting "caw caw" and emphasizing its role as a leading meme coin, particularly within the Cronos ecosystem. Discussions highlight its multi-chain presence and deflationary mechanisms, sparking interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of cancer therapy developer Kronos Bio Inc. (<a class="mention" data-mention="$KRON" data-symbol-id="KRON" href="https://stocktwits.com/symbol/KRON" target="_blank">$KRON</a>) surged over 13% to hit their highest level since Nov. 6, with trading volume spiking more than six times the daily average.&nbsp;The jump came after the company announced a drastic workforce reduction of approximately 83% by the end of the year.&nbsp;The company said this move is part of a broader strategy to implement cost-cutting measures while exploring potential business combinations and/or divesting its remaining preclinical assets to maximize shareholder value.Also, Kronos Bio revealed a leadership change: Deborah Knobelman will be appointed President and Interim CEO, effective Dec. 3.&nbsp;Knobelman will take over from Norbert Bischofberger, who has been with the company since 2018 and will step down to remain on the Board of Directors and serve as an adviser.<figure class="image"><a href="https://stocktwits.com/symbol/KRON"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_27_at_8_56_24_PM_7fc5adb6e1.png" alt="Screenshot 2024-11-27 at 8.56.24 PM.png" width="1318" height="318"></a><figcaption>KRON sentiment and message volume on Nov 27 as of 10:35 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits climbed higher within the ‘extremely bullish’ territory, accompanied by a significant increase in message volume.&nbsp;<stembedurl>https://stocktwits.com/youspeaktome/message/594265060</stembedurl>The workforce reduction follows an earlier 21% cut announced in March, with Kronos Bio estimating a $3.7 million charge related to the layoffs.&nbsp;As of March 2024, the company reportedly had 62 full-time employees and one part-time employee.Over a week ago, Piper Sandler had lowered its price target on Kronos Bio from $6 to $1 after the company halted development of its lead candidate, istisociclib, due to some adverse events in ovarian cancer patients.&nbsp;Kronos Bio’s stock has fallen around 31% year-to-date, but the latest developments appears to have rekindled optimism among retail investors.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crvo-stock-surges-on-fda-nod-for-ftd-treatment/cJI0xvNRWB">CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled</a>

Kronos Bio’s stock has fallen around 31% year-to-date, but the latest developments appears to have rekindled optimism.

Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up

The company said this move is part of a broader strategy to implement cost-cutting measures.

Equity

The company said this move is part of a broader strategy to implement cost-cutting measures.


Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half...

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for...

Piper Sandler Remains a Buy on Kronos Bio (KRON)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Kronos Bio (KRON Research Report), with a price target...

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today...

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

Company eliminates three executive officer roles and appoints new Executive Leadership teamSAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq...

Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Declines By 10.7%

Kronos Bio, Inc. (NASDAQ:KRON  Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,430,000 shares, a...

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '24	-$0.29	-$0.43	-47.11%	MISSED
Q3 '24	-$0.28	-$0.23	17.12%	BEAT
Q2 '24	-$0.34	-$0.27	19.40%	BEAT
Q1 '24	-$0.42	-$0.50	-18.34%	MISSED
Q4 '23	-$0.54	-$0.43	19.88%	BEAT

KRON
Kronos Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '24

Historical Earnings

Latest KRON News

KRON Kronos Bio Inc